SOST

Global Postmenopausal Osteoporosis Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Health, Pharmaceutical, Patient, News, Osteoporosis, Clinical trial, Discovery, RANK, SOST, Route, Company, Therapy, Teva Pharmaceuticals, II, Eli Lilly and Company, Administration, Immunoglobulin G, Route of administration, III, Dietary supplement, Pharmaceutical industry, Denosumab, Menopause

The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Postmenopausal osteoporosis - Pipeline Insight, 2021 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape.
  • Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of postmenopausal osteoporosis.
  • Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.